Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 46

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 46
---
, except per share data)

    For the Year Ended December 31,

    2024

    2023

    2022

    Revenues:

    Products, net
     
    $
    1,787,960

    $
    1,144,876

    $
    843,769

    Collaboration and other

    114,019

    98,460

    89,244

    Total revenues

    1,901,979

    1,243,336

    933,013

    Cost and expenses:

    Cost of sales (excluding amortization of in-licensed rights)

    319,099

    150,343

    139,989

    Research and development

    804,522

    877,387

    877,090

    Selling, general and administrative

    557,872

    481,871

    451,421

    Amortization of in-licensed rights

    2,405

    1,559

    714

    Total cost and expenses

    1,683,898

    1,511,160

    1,469,214

    Operating income (loss)

    218,081

    (267,824
    )

    (536,201
    )

    Other income (loss), net:

    Other income (expense), net

    42,693

    33,055

    (28,321
    )

    Loss on debt extinguishment

    —

    (387,329
    )

    (125,441
    )

    Gain from sale of Priority Review Voucher

    —

    102,000

    —

    Total other income (loss), net

    42,693

    (252,274
    )

    (153,762
    )

    Income (loss) before income tax expense

    260,774

    (520,098
    )

    (689,963
    )

    Income tax expense

    25,535

    15,879

    13,525

    Net income (loss)
     
    $
    235,239

    $
    (535,977
    )
     
    $
    (703,488
    )

    Other comprehensive income (loss):

    Unrealized (losses) gains on investments, net of